---
title: "afp clinical answers"
year: 2024
month: 10
journal: "American Family Physician"
volume: "109-110"
issue: "10"
pages: ""
doi: ""
pmid: ""
source: "PDF Extraction"
pdf_available: true
original_pdf: "2024-10-afp-clinical-answers.pdf"
extracted_date: "2025-08-10"
keywords: []
evidence_level: ""
clinical_significance: ""
---

# afp clinical answers

AFP Clinical Answers

RSV, Testosterone Therapy, Prenatal Medication Risk,
Obstructive Sialadenitis, Conjunctivitis, Gout
Does a single intramuscular injection of                                What is the recommended treatment for
nirsevimab (Beyfortus) reduce the likelihood of                         obstructive sialadenitis?
hospitalization for respiratory syncytial virus                         Sialagogues, massage, heat, and hydration are part of the initial
(RSV) in infants who do not meet criteria for                           conservative management of obstructive sialadenitis.
receiving palivizumab?
                                                                        Read more: Salivary Gland Disorders: Rapid Evidence
Palivizumab is a monoclonal antibody given as a monthly                 Review; June 2024
injection during the winter to infants at high risk of RSV com-
plications. A large industry-sponsored, randomized controlled
trial showed that a single intramuscular dose of nirsevimab             Does delayed antibiotic prescribing for
administered to average-risk infants during the winter reduced          acute bacterial conjunctivitis lead to worse
the likelihood of hospitalization due to RSV. Nirsevimab is less        therapeutic outcomes?
expensive than palivizumab and requires only a single dose.
                                                                        For acute bacterial conjunctivitis, delayed antibiotic prescribing
Read more: Single Intramuscular Dose of Nirsevimab Reduces              resulted in similar symptom control as immediate prescribing
Likelihood of Hospitalization Due to RSV in Average-Risk                while reducing antibiotic use by 50%.
Infants During First Year of Life [POEMs]; May 2024
                                                                        Read more: Conjunctivitis: Diagnosis and Management;
                                                                        August 2024
What are the main benefits of testosterone
replacement therapy for male hypogonadism?                              Is a baseline serum urate level in adults with
Testosterone replacement therapy for male hypogonadism leads            a history of gout accurate for predicting the risk
to modest improvements in sexual function and depressive                of subsequent gout flare-ups?
symptoms. Patients with heart disease or high cardiovascular
                                                                        According to a retrospective study from the United Kingdom
risk should be counseled that, despite mixed evidence, recent
                                                                        that included 3,613 adult patients, in those with a history of
data show that testosterone replacement therapy does not appear
                                                                        gout, higher baseline serum urate levels were associated with
to increase the risk of myocardial infarction, stroke, or cardio-
                                                                        an increased risk of subsequent gout flare-ups and rates of
vascular death.
                                                                        hospitalization for recurrent gout. Rates of acute gout flare-ups
Read more: Testosterone Replacement Therapy                             per 1,000 person-years were 10.6 for patients with baseline urate
for Male Hypogonadism; June 2024                                        levels less than 6 mg per dL; 40.1 for levels 6.0 to 6.9 mg per dL;
                                                                        82.0 for levels 7.0 to 7.9 mg per dL; 101.3 for levels 8.0 to 8.9 mg
                                                                        per dL; 125.3 for levels 9.0 to 9.9 mg per dL; and 132.8 for levels
Does prenatal exposure to lamotrigine,
                                                                        10 mg per dL or greater.
topiramate, or valproate increase rates of
autism?                                                                 Read more: Baseline Urate Level in Adults With History
                                                                        of Acute Gout Is Associated With the Risk of Subsequent
In a cohort study of more than 28,000 pregnant patients with            Gout Flare-ups [POEMs]; June 2024
a seizure disorder, use of lamotrigine was not associated with
an increase in the diagnosis of autism spectrum disorder among
offspring compared with no treatment during pregnancy. Use of
topiramate was associated with an increase of about 2 percentage           Tip for Using AFP at the Point of Care
points, and use of valproate was associated with an increase of            Looking for more POEMs? You can find AFP’s collection
more than 6 percentage points.                                             of POEMs at https://www.aafp.org/afp/poems. All

Read more: Similar Rates of Autism With Lamotrigine,                       department collections are available at http://www.aafp.

Topiramate, and No Treatment; Rate With Valproate                          org/afp/departments.

Is Higher [POEMs]; July 2024                                               A collection of AFP Clinical Answers is available at https://
                                                                           www.aafp.org/afp/answers.



               Downloaded from the American Family Physician website at www.aafp.org/afp. Copyright © 2024 American Acad-
October 2024 • Volume 110, Number 4                                                                               American Family Physician 345
               emy of Family Physicians. For the private, noncommercial use of one individual user of the website. All other rights
                         reserved. Contact copyrights@aafp.org for copyright questions and/or permission requests.
